Jeff Settleman named senior VP, group head of oncology R&D at Pfizer

Most Favored Nation drug pricing could put China on top

China’s biotech sector is rapidly becoming a global innovation powerhouse. In oncology alone, Chinese licensing deals reached $30 billion in 2024—triple the United States’ output. Nearly a third of the world’s clinical trials now take place in China.

April 17, 2026

By John Stanford

Bridging communication and genomics: A path toward equitable cancer care

The era of genomic oncology is defined by complexity. Over the last decades, we have moved from single-gene tests to multi-gene panels and, eventually, will be routinely using whole-exome/whole-genome and transcriptome sequencing in clinical care.

April 17, 2026

By Stacy W. Gray

Cancer Policy

FDA adds stereotactic breast biopsy needles to the shortage list

FDA has added stereotactic breast biopsy needles to its Medical Device Shortages List with an estimated duration of “through Q4 2026,” which spans July 1 to Sept. 30.

April 17, 2026

By Jacquelyn Cobb

Cancer Policy

CMS proposed rule would implement electronic prior authorization requirements for covered drugs in federal health plans

The Centers for Medicare & Medicaid Services issued the 2026 CMS Interoperability Standards and Prior Authorization for Drugs proposed rule, which aims to shorten care delays and improve transparency within federal health insurance programs by establishing electronic prior authorization, or ePA, requirements for covered prescription drugs and expedite federal response deadlines to ensure patients receive life-critical medications without administrative delay.

April 17, 2026

By Jacquelyn Cobb

Cancer Policy

At Friends meeting, data quality, modern evidence generation, and early regulatory alignment top the list of “next steps” for external control arms

A meeting convened by Friends of Cancer Research focused on the methodology for using external control arms in cancer clinical trials.

April 17, 2026

By Jacquelyn Cobb

Cancer Policy

ACIP charter is renewed as meetings remain on indefinite hold

The Advisory Committee on Immunization Practices, or ACIP, renewed its charter April 6. In an announcement in the Federal Register, new criteria for ACIP members were rolled out with a focus on “geographical balance” and a “balance of speciality areas.”

April 17, 2026

By Jacquelyn Cobb

Jeff Settleman named senior VP, group head of oncology R&D at Pfizer

YOU MAY BE INTERESTED IN

Most Favored Nation drug pricing could put China on top

Bridging communication and genomics: A path toward equitable cancer care

FDA adds stereotactic breast biopsy needles to the shortage list

CMS proposed rule would implement electronic prior authorization requirements for covered drugs in federal health plans

At Friends meeting, data quality, modern evidence generation, and early regulatory alignment top the list of “next steps” for external control arms

ACIP charter is renewed as meetings remain on indefinite hold

Renew today!

Subscriber content

Never miss an issue!

Login